United Statesaptar.com/en-us/pharmaceutical
Owner Investor / Financier Operator Developer
Aptar Pharma, a division of AptarGroup, Inc., is a global leader in drug delivery systems and dispensing technologies for the pharmaceutical industry. Headquartered in Crystal Lake, Illinois, AptarGroup designs and manufactures innovative dosing, dispensing, and protection solutions, with Aptar Pharma specializing in devices for nasal, pulmonary, ophthalmic, dermal, injectable, and oral applications.
The division supports pharmaceutical companies from drug formulation through commercialization, offering expertise in therapeutic areas including asthma/COPD, allergic rhinitis, pain management, CNS treatments, vaccines, biologics, and small molecules. Key technologies encompass preservative-free multidose systems, airless packaging, bag-on-valve, active material science, and digital health solutions to enhance patient outcomes and adherence.
Aptar Pharma operates 15 GMP-certified manufacturing sites worldwide, spanning 120,000 m² with 3,500 employees producing 8 billion systems annually for over 1,500 customers. Relevant to the chemical industry, its elastomeric components, valves, pumps, and active packaging ensure stability, preservation, and precise delivery of chemical formulations in healthcare products.
Also known as Aptar.
chemXplore tracks 1 project involving Aptar Pharma.
Adds Kolibri NPLI platform to support complex inhaled therapies including biologics, and integrates formulation, device, regulatory and digital services for end‑to‑end development.
CE marking for a LuerLock‑compatible intranasal device and optional Spray Divider that delivers two sequential sprays (200 µL, 500 µL), supporting vaccine development from early clinical to commercial.
Adds local production of pMDI valves, breath‑actuated inhalation devices and multi dose nasal spray systems; site grows to 11,300 m² to improve regional supply resilience.
Partners will create an integrated translational platform to quantify mechanisms, pathways and kinetics of nose-to-brain drug transport using in vitro, in vivo and computational tools.
APF multidose preservative‑free pump line commissioned to serve Latin American markets, cutting lead times and improving local supply agility.
AI analyzes device-generated sounds to verify correct operation and provide objective feedback for training, usability studies and adherence in home self-administration.
Published three international patent applications for nasal/pulmonary GLP‑1 formulations (spray‑dried/powder). Preclinical semaglutide PK shows up to 10× Cmax vs oral; ongoing biologics delivery work.
Powder nasal device used in a Phase II trial of a once-weekly spray to assess safety, tolerability and reduction of symptomatic infections; device offers single-dose precision and moisture protection.
active all projects
